Orchestra BioMed (OBIO) presented its strategic partnership model and financial health at the Wells Fargo 21st Annual Healthcare Conference. The company, which has raised $185 million from strategic partners and investors, including Medtronic, Terumo, and Ligand, owns 21% of its shares. Orchestra BioMed's market capitalization stands at $358 million, with a stock price of $6.00, reflecting a 109% return over the past year. Wall Street analysts have price targets ranging from $9 to $20.
The company's financial health is characterized by a current ratio of 8.26 and a levered free cash flow of negative $59 million, funded through 2027. Orchestra BioMed is focused on innovation and clinical execution, structuring win-win risk/reward partnerships with strategic partners. The company's CEO, David Hochman, emphasized the importance of proving clinical benefit and partnering for scale.
Orchestra BioMed's AVIM therapy is intended to be an 'always-on' treatment for patients with hypertension and heart failure risk. The BACKBEAT study, a global pivotal trial, has enrolled 284 patients, with primary efficacy data expected in the second quarter of 2025. The FDA submission for AVIM is expected around the same time. U.S. commercialization is anticipated in the first half of 2028, with a global rollout throughout 2028.
The MODERATO II pilot study for AVIM showed a 97% qualification rate for randomization, with an average 13.2-millimeter drop in ambulatory systolic blood pressure. The Virtue SAB, a sirolimus angioinfusion balloon, has shown promising results in the single-layer in-stent restenosis cohort, with a target lesion failure rate of 2.8% at one year, compared to 13.5% for Boston Scientific's AGENT balloon.
The company's initial launch market for AVIM includes over 1 million pacemaker patients with hypertension yearly, with a global addressable market of up to $16 billion. The coronary intervention market, which includes drug-coated balloons, is valued at $7.5 billion, with a shift towards leave-nothing-behind treatments. Orchestra BioMed's lean operational structure consists of about 100 employees, with senior leadership including eight former chief executives from clinical-stage medical device companies.
